Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients

Lu Huber, Nils Lachmann, Matthias Niemann, Marcel Naik, Lutz Liefeldt, Petra Glander, Danilo Schmidt, Fabian Halleck, Johannes Waiser, Susanne Brakemeier, Hans H. Neumayer, Constanze Schönemann, Klemens Budde

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Virtual panel-reactive antibodies (vPRA) have been implemented to gauge sensitization worldwide. It is unclear how it associates with long-term outcomes, and its correlation with peak (pPRA) or actual (aPRA) has not been studied. We retrospectively reviewed data from 18- to 65-year-old kidney-only transplant patients during 1.1.1996-31.7.2011 in our center. PRAs were calculated based on solid-phase techniques. Of the 726 qualified cases, regardless of the PRA type, sensitized patients (PRA > 5%) had more females and previous transplant. Highly sensitized (HS, PRA > 50%) had longer waiting time, lower transplant rate, less living donor, more delayed graft function, and acute rejection. The conformity between vPRA and pPRA in HS was 75%, 57% between pPRA and aPRA. Forty-three percent (61/142) patients whose pPRA was >5% had no detectable aPRA and maintained similar outcomes as sensitized patients. Multivariate analysis showed consistently lower death-censored graft survival in HS defined by vPRA [HR 2.086 (95% CI 1.078-4.037), P < 0.05] and pPRA [HR 2.139 (95% CI 1.024-4.487), P < 0.05]. Both vPRA and pPRA provided reliable way estimating sensitization and predicting long-term graft survival, while aPRA might underestimate true sensitization. vPRA might be the most objective parameter to gauge sensitization.

Original languageEnglish (US)
Pages (from-to)710-719
Number of pages10
JournalTransplant International
Volume28
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Kidney
Antibodies
Graft Survival
Transplants
Delayed Graft Function
Living Donors
Multivariate Analysis
Transplant Recipients

Keywords

  • graft survival
  • panel-reactive antibodies
  • sensitization
  • virtual PRA

ASJC Scopus subject areas

  • Transplantation

Cite this

Huber, L., Lachmann, N., Niemann, M., Naik, M., Liefeldt, L., Glander, P., ... Budde, K. (2015). Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. Transplant International, 28(6), 710-719. https://doi.org/10.1111/tri.12533

Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. / Huber, Lu; Lachmann, Nils; Niemann, Matthias; Naik, Marcel; Liefeldt, Lutz; Glander, Petra; Schmidt, Danilo; Halleck, Fabian; Waiser, Johannes; Brakemeier, Susanne; Neumayer, Hans H.; Schönemann, Constanze; Budde, Klemens.

In: Transplant International, Vol. 28, No. 6, 01.01.2015, p. 710-719.

Research output: Contribution to journalArticle

Huber, L, Lachmann, N, Niemann, M, Naik, M, Liefeldt, L, Glander, P, Schmidt, D, Halleck, F, Waiser, J, Brakemeier, S, Neumayer, HH, Schönemann, C & Budde, K 2015, 'Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients', Transplant International, vol. 28, no. 6, pp. 710-719. https://doi.org/10.1111/tri.12533
Huber L, Lachmann N, Niemann M, Naik M, Liefeldt L, Glander P et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. Transplant International. 2015 Jan 1;28(6):710-719. https://doi.org/10.1111/tri.12533
Huber, Lu ; Lachmann, Nils ; Niemann, Matthias ; Naik, Marcel ; Liefeldt, Lutz ; Glander, Petra ; Schmidt, Danilo ; Halleck, Fabian ; Waiser, Johannes ; Brakemeier, Susanne ; Neumayer, Hans H. ; Schönemann, Constanze ; Budde, Klemens. / Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. In: Transplant International. 2015 ; Vol. 28, No. 6. pp. 710-719.
@article{f5e3abcd525c41f5ab0ea1dbc74d67cb,
title = "Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients",
abstract = "Virtual panel-reactive antibodies (vPRA) have been implemented to gauge sensitization worldwide. It is unclear how it associates with long-term outcomes, and its correlation with peak (pPRA) or actual (aPRA) has not been studied. We retrospectively reviewed data from 18- to 65-year-old kidney-only transplant patients during 1.1.1996-31.7.2011 in our center. PRAs were calculated based on solid-phase techniques. Of the 726 qualified cases, regardless of the PRA type, sensitized patients (PRA > 5{\%}) had more females and previous transplant. Highly sensitized (HS, PRA > 50{\%}) had longer waiting time, lower transplant rate, less living donor, more delayed graft function, and acute rejection. The conformity between vPRA and pPRA in HS was 75{\%}, 57{\%} between pPRA and aPRA. Forty-three percent (61/142) patients whose pPRA was >5{\%} had no detectable aPRA and maintained similar outcomes as sensitized patients. Multivariate analysis showed consistently lower death-censored graft survival in HS defined by vPRA [HR 2.086 (95{\%} CI 1.078-4.037), P < 0.05] and pPRA [HR 2.139 (95{\%} CI 1.024-4.487), P < 0.05]. Both vPRA and pPRA provided reliable way estimating sensitization and predicting long-term graft survival, while aPRA might underestimate true sensitization. vPRA might be the most objective parameter to gauge sensitization.",
keywords = "graft survival, panel-reactive antibodies, sensitization, virtual PRA",
author = "Lu Huber and Nils Lachmann and Matthias Niemann and Marcel Naik and Lutz Liefeldt and Petra Glander and Danilo Schmidt and Fabian Halleck and Johannes Waiser and Susanne Brakemeier and Neumayer, {Hans H.} and Constanze Sch{\"o}nemann and Klemens Budde",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/tri.12533",
language = "English (US)",
volume = "28",
pages = "710--719",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients

AU - Huber, Lu

AU - Lachmann, Nils

AU - Niemann, Matthias

AU - Naik, Marcel

AU - Liefeldt, Lutz

AU - Glander, Petra

AU - Schmidt, Danilo

AU - Halleck, Fabian

AU - Waiser, Johannes

AU - Brakemeier, Susanne

AU - Neumayer, Hans H.

AU - Schönemann, Constanze

AU - Budde, Klemens

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Virtual panel-reactive antibodies (vPRA) have been implemented to gauge sensitization worldwide. It is unclear how it associates with long-term outcomes, and its correlation with peak (pPRA) or actual (aPRA) has not been studied. We retrospectively reviewed data from 18- to 65-year-old kidney-only transplant patients during 1.1.1996-31.7.2011 in our center. PRAs were calculated based on solid-phase techniques. Of the 726 qualified cases, regardless of the PRA type, sensitized patients (PRA > 5%) had more females and previous transplant. Highly sensitized (HS, PRA > 50%) had longer waiting time, lower transplant rate, less living donor, more delayed graft function, and acute rejection. The conformity between vPRA and pPRA in HS was 75%, 57% between pPRA and aPRA. Forty-three percent (61/142) patients whose pPRA was >5% had no detectable aPRA and maintained similar outcomes as sensitized patients. Multivariate analysis showed consistently lower death-censored graft survival in HS defined by vPRA [HR 2.086 (95% CI 1.078-4.037), P < 0.05] and pPRA [HR 2.139 (95% CI 1.024-4.487), P < 0.05]. Both vPRA and pPRA provided reliable way estimating sensitization and predicting long-term graft survival, while aPRA might underestimate true sensitization. vPRA might be the most objective parameter to gauge sensitization.

AB - Virtual panel-reactive antibodies (vPRA) have been implemented to gauge sensitization worldwide. It is unclear how it associates with long-term outcomes, and its correlation with peak (pPRA) or actual (aPRA) has not been studied. We retrospectively reviewed data from 18- to 65-year-old kidney-only transplant patients during 1.1.1996-31.7.2011 in our center. PRAs were calculated based on solid-phase techniques. Of the 726 qualified cases, regardless of the PRA type, sensitized patients (PRA > 5%) had more females and previous transplant. Highly sensitized (HS, PRA > 50%) had longer waiting time, lower transplant rate, less living donor, more delayed graft function, and acute rejection. The conformity between vPRA and pPRA in HS was 75%, 57% between pPRA and aPRA. Forty-three percent (61/142) patients whose pPRA was >5% had no detectable aPRA and maintained similar outcomes as sensitized patients. Multivariate analysis showed consistently lower death-censored graft survival in HS defined by vPRA [HR 2.086 (95% CI 1.078-4.037), P < 0.05] and pPRA [HR 2.139 (95% CI 1.024-4.487), P < 0.05]. Both vPRA and pPRA provided reliable way estimating sensitization and predicting long-term graft survival, while aPRA might underestimate true sensitization. vPRA might be the most objective parameter to gauge sensitization.

KW - graft survival

KW - panel-reactive antibodies

KW - sensitization

KW - virtual PRA

UR - http://www.scopus.com/inward/record.url?scp=84929300453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929300453&partnerID=8YFLogxK

U2 - 10.1111/tri.12533

DO - 10.1111/tri.12533

M3 - Article

C2 - 25639331

AN - SCOPUS:84929300453

VL - 28

SP - 710

EP - 719

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 6

ER -